Tectonic sees top-line results from a Phase 2 trial of TX45 in PH with heart failure with preserved ejection fraction by ...

Mannkind and United Therapeutics are creating an inhaled formulation of ralinepag, an experimental oral PAH treatment.

Treatment with treprostinil led to significant and sustained improvements in children with PH associated with lung disease, ...

Corvista Health and Mayo Clinic will study whether Corvista-PH can improve pulmonary hypertension diagnosis and referrals.

“This study provides comprehensive preclinical evidence that the novel PDE5 inhibitor CPD1 is a potent therapeutic candidate ...

The analysis revealed dozens of genes with abnormal expression in cells from people with idiopathic PAH, and the researchers ...

World Pulmonary Hypertension Day 2026 highlights hope through clinical trials for the global disease community.

Pulmonary hypertension (PH) is caused by high blood pressure in the lungs, which is caused by narrowed and thickened pulmonary arteries. Because of the added effort needed to pump blood through the ...

Although there is no cure yet for pulmonary hypertension (PH), there are a variety of therapies available that can help manage the symptoms of the disease and maintain or improve the quality of life ...

Pulmonary hypertension (PH) is characterized by high blood pressure, which affects the pulmonary arteries, the vessels that transport blood from the heart to the lungs. Due to the thickened and ...

Treatment with mosliciguat, an inhaled medication given once-daily for pulmonary hypertension (PH), can safely reduce the resistance against blood flow in blood vessels of the lungs, according to a ...